Literature DB >> 6812745

Acceleration of ventricular rate by fibrillation associated with the Wolff-Parkinson-White syndrome.

B D Sheinman, T Evans.   

Abstract

Amiodarone has proved to be a valuable drug in atrial fibrillation associated with the Wolff-Parkinson-White syndrome. When it was administered to a patient with this syndrome in atrial fibrillation, who had previously suffered an inferior myocardial infarction, the ventricular rate accelerated from 170 to 230 beats/minute.This unusual case emphasises the need for full electrophysiological assessment of patients with the Wolff-Parkinson-White syndrome for whom amiodarone treatment is being considered.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6812745      PMCID: PMC1500376          DOI: 10.1136/bmj.285.6347.999

Source DB:  PubMed          Journal:  Br Med J (Clin Res Ed)        ISSN: 0267-0623


  5 in total

1.  Control of tachyarrhythmias associated with Wolff-Parkinson-White syndrome by amiodarone hydrochloride.

Authors:  M B Rosenbaum; P A Chiale; D Ryba; M V Elizari
Journal:  Am J Cardiol       Date:  1974-08       Impact factor: 2.778

2.  Ventricular fibrillation. A possible mechanism of sudden death in patients and Wolff-Parkinson-White syndrome.

Authors:  L S Dreifus; R Haiat; Y Watanabe; J Arriaga; N Reitman
Journal:  Circulation       Date:  1971-04       Impact factor: 29.690

3.  Effect of drugs in the Wolff-Parkinson-White syndrome. Importance of initial length of effective refractory period of the accessory pathway.

Authors:  H J Wellens; F W Bär; W R Dassen; P Brugada; E J Vanagt; J Farré
Journal:  Am J Cardiol       Date:  1980-10       Impact factor: 2.778

4.  Effect of amiodarone in the Wolff-Parkinson-White syndrome.

Authors:  H J Wellens; K I Lie; F W Bär; J C Wesdorp; H J Dohmen; D R Düren; D Durrer
Journal:  Am J Cardiol       Date:  1976-08       Impact factor: 2.778

5.  Electrophysiological assessment of amiodarone in treatment of resistant supraventricular arrhythmias.

Authors:  E Rowland; D M Krikler
Journal:  Br Heart J       Date:  1980-07
  5 in total
  6 in total

Review 1.  Challenging the superiority of amiodarone for rate control in Wolff-Parkinson-White and atrial fibrillation.

Authors:  Sharis M Simonian; Shahram Lotfipour; Christopher Wall; Mark I Langdorf
Journal:  Intern Emerg Med       Date:  2010-05-01       Impact factor: 3.397

Review 2.  Assessment of the risk-benefit ratio for antiarrhythmic drug use.

Authors:  R W Campbell
Journal:  Drugs       Date:  1988-11       Impact factor: 9.546

3.  Executive Summary: European Heart Rhythm Association Consensus Document on the Management of Supraventricular Arrhythmias: Endorsed by Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulación Cardiaca y Electrofisiologia (SOLAECE).

Authors:  Demosthenes G Katritsis; Giuseppe Boriani; Francisco G Cosio; Pierre Jais; Gerhard Hindricks; Mark E Josephson; Roberto Keegan; Bradley P Knight; Karl-Heinz Kuck; Deirdre A Lane; Gregory Yh Lip; Helena Malmborg; Hakan Oral; Carlo Pappone; Sakis Themistoclakis; Kathryn A Wood; Kim Young-Hoon; Carina Blomström Lundqvist
Journal:  Arrhythm Electrophysiol Rev       Date:  2016

4.  Acceleration of the ventricular response to atrial flutter by amiodarone in an infant with Wolff-Parkinson-White syndrome.

Authors:  J A Till; M Baxendall; A Benetar
Journal:  Br Heart J       Date:  1993-07

Review 5.  Amiodarone. An overview of its pharmacological properties, and review of its therapeutic use in cardiac arrhythmias.

Authors:  J Gill; R C Heel; A Fitton
Journal:  Drugs       Date:  1992-01       Impact factor: 9.546

6.  Efficacy of Nifekalant in Patients With Wolff-Parkinson-White Syndrome and Atrial Fibrillation: Electrophysiological and Clinical Findings.

Authors:  Jinzhu Hu; Jianhua Yu; Qi Chen; Jianxin Hu; Qianghui Huang; Zhen Xia; Zirong Xia; Zhenzhen Ju; Ping Yuan; Siyang Fan; Qinmei Xiong; Bo Zhu; Lin Huang; Chunjiao You; Huihui Bao; Yanqing Wu; Xiaoshu Cheng; Juxiang Li; Ali J Marian; Kui Hong
Journal:  J Am Heart Assoc       Date:  2019-06-25       Impact factor: 5.501

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.